Abstract
Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.
| Original language | English |
|---|---|
| Pages (from-to) | 58-62 |
| Number of pages | 5 |
| Journal | Journal of Pharmacy and Pharmacology |
| Volume | 46 |
| Issue number | 1 |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
Cite this
Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide. / Sheu, J. R.; Huang, T. F.
In: Journal of Pharmacy and Pharmacology, Vol. 46, No. 1, 1994, p. 58-62.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide
AU - Sheu, J. R.
AU - Huang, T. F.
PY - 1994
Y1 - 1994
N2 - Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.
AB - Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.
UR - http://www.scopus.com/inward/record.url?scp=0027976903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027976903&partnerID=8YFLogxK
M3 - Article
C2 - 8201528
AN - SCOPUS:0027976903
VL - 46
SP - 58
EP - 62
JO - Journal of Pharmacy and Pharmacology
JF - Journal of Pharmacy and Pharmacology
SN - 0022-3573
IS - 1
ER -